Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA.

IF 3.7 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Aaron King, Xi Tan, Neil Dhopeshwarkar, Rhonda Bohn, Katherine Dea, Charles E Leonard, Adam de Havenon
{"title":"Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA.","authors":"Aaron King, Xi Tan, Neil Dhopeshwarkar, Rhonda Bohn, Katherine Dea, Charles E Leonard, Adam de Havenon","doi":"10.1136/bmjdrc-2024-004431","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to assess recent trends in the US use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) in people with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), including incident use following newly diagnosed ASCVD.</p><p><strong>Research design and methods: </strong>This real-world, retrospective observational study used de-identified data from the TriNetX Dataworks-USA network. A longitudinal analysis of cross-sectional data (interval: January 01, 2018 to December 31, 2022) assessed the yearly prevalent use of GLP-1 RA and SGLT2i. A nested cohort study (January 01, 2017 to January 31, 2023) assessed the proportions of patients with T2D newly prescribed GLP-1 RAs and SGLT2is after incident ASCVD diagnosis.</p><p><strong>Results: </strong>Prevalent use of GLP-1 RA and/or SGLT2i increased from 9.2% of patients in 2018 to 27.1% in 2022, with eligible annual patient numbers ranging from 279,474 to 348,997. GLP-1 RA-alone use rose from 5.2% to 9.9% and SGLT2i-alone use rose from 2.8% to 12.2% over this interval. Incident use of GLP-1 RA and/or SGLT2i within the year following ASCVD diagnosis increased from 5.9% to 17.0% (2018-2022). For GLP-1 RA alone, this increase was from 3.6% to 7.8%, while for SGLT2i alone, it was from 1.8% to 7.0%.</p><p><strong>Conclusions: </strong>Use of GLP-1 RAs/SGLT2is in patients with T2D and ASCVD has increased in recent years in the USA, but remains suboptimal given the prevalence of ASCVD and its high morbidity and mortality.</p>","PeriodicalId":9151,"journal":{"name":"BMJ Open Diabetes Research & Care","volume":"12 5","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459310/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Diabetes Research & Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjdrc-2024-004431","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: This study aimed to assess recent trends in the US use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) in people with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), including incident use following newly diagnosed ASCVD.

Research design and methods: This real-world, retrospective observational study used de-identified data from the TriNetX Dataworks-USA network. A longitudinal analysis of cross-sectional data (interval: January 01, 2018 to December 31, 2022) assessed the yearly prevalent use of GLP-1 RA and SGLT2i. A nested cohort study (January 01, 2017 to January 31, 2023) assessed the proportions of patients with T2D newly prescribed GLP-1 RAs and SGLT2is after incident ASCVD diagnosis.

Results: Prevalent use of GLP-1 RA and/or SGLT2i increased from 9.2% of patients in 2018 to 27.1% in 2022, with eligible annual patient numbers ranging from 279,474 to 348,997. GLP-1 RA-alone use rose from 5.2% to 9.9% and SGLT2i-alone use rose from 2.8% to 12.2% over this interval. Incident use of GLP-1 RA and/or SGLT2i within the year following ASCVD diagnosis increased from 5.9% to 17.0% (2018-2022). For GLP-1 RA alone, this increase was from 3.6% to 7.8%, while for SGLT2i alone, it was from 1.8% to 7.0%.

Conclusions: Use of GLP-1 RAs/SGLT2is in patients with T2D and ASCVD has increased in recent years in the USA, but remains suboptimal given the prevalence of ASCVD and its high morbidity and mortality.

美国 2 型糖尿病和动脉粥样硬化性心血管疾病患者使用 GLP-1 RA 和 SGLT2i 的最新趋势。
简介:本研究旨在评估美国 2 型糖尿病(T2D)和动脉粥样硬化性心血管疾病(ASCVD)患者使用胰高血糖素样肽-1 受体激动剂(GLP-1 RA)和钠-葡萄糖共转运体 2 抑制剂(SGLT2i)的最新趋势,包括新诊断出 ASCVD 后的使用情况:这项真实世界的回顾性观察研究使用了来自 TriNetX Dataworks-USA 网络的去标识化数据。横断面数据的纵向分析(时间间隔:2018 年 1 月 1 日至 2022 年 12 月 31 日)评估了 GLP-1 RA 和 SGLT2i 的年度普遍使用情况。一项嵌套队列研究(2017 年 1 月 1 日至 2023 年 1 月 31 日)评估了在发生 ASCVD 诊断后新处方 GLP-1 RA 和 SGLT2i 的 T2D 患者比例:GLP-1 RA和/或SGLT2i的普遍使用率从2018年的9.2%增至2022年的27.1%,符合条件的年度患者人数从279,474人到348,997人不等。在此期间,GLP-1 RA 单药使用率从 5.2% 上升至 9.9%,SGLT2i 单药使用率从 2.8% 上升至 12.2%。在确诊 ASCVD 后的一年内,GLP-1 RA 和/或 SGLT2i- 的使用率从 5.9% 上升至 17.0%(2018-2022 年)。对于 GLP-1 RA 而言,这一比例从 3.6% 增加到 7.8%,而对于 SGLT2i 而言,这一比例从 1.8% 增加到 7.0%:近年来,在美国,GLP-1 RAs/SGLT2i 在 T2D 和 ASCVD 患者中的使用有所增加,但鉴于 ASCVD 的发病率及其高发病率和死亡率,其效果仍未达到最佳。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMJ Open Diabetes Research & Care
BMJ Open Diabetes Research & Care Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
9.30
自引率
2.40%
发文量
123
审稿时长
18 weeks
期刊介绍: BMJ Open Diabetes Research & Care is an open access journal committed to publishing high-quality, basic and clinical research articles regarding type 1 and type 2 diabetes, and associated complications. Only original content will be accepted, and submissions are subject to rigorous peer review to ensure the publication of high-quality — and evidence-based — original research articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信